SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB:ADMP) announced on July 23 that its wholly owned subsidiary, Adamis Labs launched and shipped the first orders of the company’s Epinephrine Injection, USP, 1:1000 (0.3mg prefilled single dose syringe) (“PFS”). Today, Adamis Labs reports that at least two major data base reference companies (Medi-Span® and First DataBank®) placed the Company’s PFS in their generic category. Thousands of healthcare professionals depend on these data base reference providers for context-relevant, integrated drug information. As a result of this generic classification, several insurance providers, including Aetna® (NYSE: AET) and Blue Cross Blue Shield of Michigan have placed Adamis’ PFS in their Tier 1 category. Tier 1 presently consists of generic drugs, and thus the patient is offered the lowest co-pay available.
